15/12/2025
GLP‑1 analogues like semaglutide, liraglutide, dulaglutide or dual GIP/GLP-1RA tirzepatide have taken the world by storm—and for some people, they can be a powerful tool. They slow stomach emptying and enhance insulin’s effects, which helps you feel fuller for longer and makes it easier to reduce overall intake. In clinical studies, people without diabetes lost around 10–15% of their body weight on semaglutide, and those with type 2 diabetes lost less—compared to placebo.
But there is fine print that rarely makes it into headlines:
• Weight loss tends to plateau after about 60–68 weeks.
• When the injections stop, weight often creeps back—sometimes significantly—because appetite hormones and old eating patterns return.
• Side effects are common: nausea, vomiting, constipation, reflux, and in rare cases, pancreatitis or gallbladder issues.
• Serious but uncommon: gallbladder disorders, inflammation of the pancreas
• Controversy whether GLP-1 agonists increase suicidal behaviour and ideation
As a pharmacist, my job is to help people weigh these trade‑offs—benefits, risks, cost. For some, GLP‑1s are a useful bridge; for others, they’re not the right fit.
If you’re wondering, “What are my alternatives if I want to address the root cause with diet, lifestyle, and inflammation control?”—that’s where my work comes in.
👉 I’ve created a science‑backed newsletter that translates complex science into plain English, with practical actions you can start immediately.�
Comment ROOT CAUSE or subscribe via my website if you’d like the next issue delivered straight to your inbox
https://theenlightenedpharmacist.com/subscribe/
References
1. Ghusn, W., & Hurtado, M. D. (2024). Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity pillars, 12, 100127. https://doi.org/10.1016/j.obpill.2024.100127
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025). Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obesity reviews : an official journal of the International Association for the Study of Obesity, 26(8), e13929. https://doi.org/10.1111/obr.13929
4. Therapeutic Goods Administration (TGA). GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours. Updated 1 December 2025. https://www.tga.gov.au/news/safety-updates/glp-1-ras-warnings-aligned-over-potential-risk-suicidal-thoughts-or-behaviours . Accessed 13 December 2025